Abcam, ab308307, Anti-Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 antibody [EPR27397-4] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Nicotinic Acetylcholine Receptor alpha 1/CHRNA1 antibody. Carrier free. Suitable for WB, IHC-P, IHC-Fr and reacts with Human, Mouse, Rat, Transfected cell line samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27397-4,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Rat, Human, Mouse,
Applications:IHC-Fr, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Nicotinic Acetylcholine Receptor alpha 1 also known as CHRNA1 is an essential component of the nicotinic acetylcholine receptor complex. This receptor an ion channel found in the neuromuscular junction is involved in the mechanical process of signal transmission between nerves and muscles. The protein facilitates the binding of acetylcholine a neurotransmitter which triggers an ion flow causing muscle contraction. The CHRNA1 subunit generally displays a mass of approximately 58 kDa and is widely expressed in muscle tissues.
Biological function summary
The Nicotinic Acetylcholine Receptor alpha 1 has a fundamental role in neuromuscular communication. It is part of a pentameric complex in combination with other acetylcholine receptor subunits. When acetylcholine binds to the receptor the channel opens permitting cations like sodium and calcium to enter the muscle cell leading to depolarization and subsequent muscle contraction. This biological process is essential for voluntary muscle movement.
Pathways
The Nicotinic Acetylcholine Receptor alpha 1 is involved in the neuromuscular signaling pathway. This pathway regulates muscle contraction by converting neural chemical signals into mechanical responses. In this pathway CHRNA1 interacts closely with proteins such as the acetylcholine ligand and acetylcholine receptor. These interactions ensure effective synaptic transmission at the neuromuscular junction contributing to muscle activation and relaxation cycles.
Nicotinic Acetylcholine Receptor alpha 1 is linked to conditions such as myasthenia gravis and congenital myasthenic syndromes. In myasthenia gravis autoantibodies targeting CHRNA1 hinder normal receptor function on muscles leading to weakness and fatigue. Additionally the protein is associated with congenital myasthenic syndromes where mutations can alter the receptor's function resulting in impaired neuromuscular transmission. The receptor's relationship with other proteins like the acetylcholine receptor and AchR protein plays an important role in these conditions often defining the severity and specific characteristics of the disorders.